You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤醫藥(03320.HK)完成收購博雅生物(300294.SZ)控股權
格隆匯 11-25 18:47

格隆匯11月25日丨華潤醫藥(03320.HK)宣佈,有關建議收購博雅生物製藥集團股份有限公司的控股權,目標公司已向華潤醫藥控股發行78,308,575股目標公司股份並已就有關股份取得深圳證券交易所上市批准。因此,於2021年11月25日,華潤醫藥控股已根據交易文件及補充交易文件的條款及條件完成建議認購。

完成建議認購後,華潤醫藥控股總共持有目標公司147,640,553股股份,佔公吿日期目標公司總股本約28.86%。連同根據交易文件及補充交易文件委託華潤醫藥控股的目標公司204,690,193股股份的表決權,於本公吿日期,華潤醫藥控股總共持有目標公司總股本40.01%表決權,華潤醫藥控股因此成為目標公司的控股股東。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account